New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
07:02 EDTSLXPSalix announces outcome for TARGET 3 study evaluating rifaximin
Salix Pharmaceuticals announced the "successful" outcome of TARGET 3, a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg TID for 14 days in subjects with irritable bowel syndrome with diarrhea, or IBS-D, who respond to an initial treatment course with rifaximin 550 mg TID for 14 days. In the study a statistically significant greater proportion of rifaximin treated subjects responded to repeat treatment as assessed by the composite primary endpoint of IBS-related abdominal pain and stool consistency during the 4 week treatment-free follow-up period in the Double Blind Repeat Treatment Phase. The company said, "The outcome of TARGET 3 serves to corroborate the results of TARGET 1 and TARGET 2, the confirmatory Phase 3 trials for our supplemental New Drug Application seeking marketing approval for rifaximin as a treatment option for irritable bowel syndrome with diarrhea.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
12:34 EDTSLXPSalix mentioned as a potential acquisition target by dealReporter
November 14, 2014
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:03 EDTSLXPSalix upgraded to Buy from Neutral at UBS
UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.
November 11, 2014
08:20 EDTSLXPSalix risk/reward remains favorable, says Leerink
Subscribe for More Information
06:14 EDTSLXPSalix risk/reward now 'more interesting,' says Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use